June 28th, 2023 | 07:40 CEST
Cardiol Therapeutics, Bayer, BASF - Sensational breakthroughs in medicine and sustainability
A study in the JACC journal shows that cardiovascular risk factors and diseases will increase sharply in the US. Ischemic heart disease is projected to increase by 31.1%, heart failure by 33.0% and myocardial infarction by 30.1%. Cardiol Therapeutics, a Canadian company specializing in cardiovascular diseases, is thus rapidly gaining in importance. Bayer goes AI and partners for the first time with a Swiss hospital for a digital solution that supports radiologists in diagnosis and treatment. BASF invests with its venture arm in the Swiss startup DePoly, which has developed an innovative chemical recycling technology. Discover the sustainable solution behind this investment here.
time to read: 4 minutes
|
Author:
Juliane Zielonka
ISIN:
CARDIOL THERAPEUTICS | CA14161Y2006 , BAYER AG NA O.N. | DE000BAY0017 , BASF SE NA O.N. | DE000BASF111
Table of contents:
"[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.
Author
Juliane Zielonka
Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.
Tag cloud
Shares cloud
Cardiol Therapeutics - Innovative heart therapy in a huge growth market
US researchers predict that the incidence of cardiovascular risk factors and diseases in the US will increase significantly in the coming decades. This is the conclusion of a study published in the renowned scientific Journal of the American College of Cardiology JACC.
The research team's estimates show clear increases in the prevalence of four cardiovascular diseases. Prevalence indicates how common a disease or condition is in a given population. A 31.1% increase in ischemic heart disease (from 21.9 to 28.7 million) is expected in the US from 2025 to 2060. The number of people with heart failure will increase by 33.0% (from 9.7 to 12.9 million), while those with myocardial infarction will increase by 30.1% (from 12.3 to 16.0 million).
This makes the work of Canadian life science company Cardiol Therapeutics all the more valuable. The Company specializes in the research and development of therapies to treat cardiovascular disease through antifibrotic and anti-inflammatory approaches.
The Company's lead product, CardiolRx, is currently in a multi-centre Phase II/III trial. This study is a randomized, double-blind, placebo-controlled investigation designed to evaluate the efficacy and safety of CardiolRx in hospitalized COVID-19 patients. In addition, CardiolRx is being evaluated for its potential to treat recurrent pericarditis and acute myocarditis.
The Company is also working to develop a subcutaneous formulation of CardiolRx that specifically targets fibrosis and inflammation in the heart. One man's grief is another man's joy. Given the alarmingly high rates of heart disease, the US, in particular, is an excellent market for Cardiol Therapeutics.
Bayer - Launches AI pilot in radiology with Swiss hospital
Bayer and the Inselspital Bern are partnering to use the Calantic™ Digital Solutions medical imaging platform. This collaboration aims to improve the clinical application of artificial intelligence (AI) in medical imaging. AI applications for medical imaging can improve prioritization, lesion detection, quantification and productivity of radiological interventions.
Through a subscription licence agreement of this specialized platform, Inselspital will use digital applications, including artificial intelligence (AI)-powered tools for medical imaging. The platform includes apps that help radiologists and their teams improve productivity, supporting healthcare professionals at different stages of their work, from diagnosis to treatment of their patients.
Bayer will also provide Inselspital Bern with services related to the installation, configuration and training of the platform and its apps. In addition, Bayer and Inselspital will jointly generate real-world clinical evidence to demonstrate the benefits of using AI, including the benefits of using a platform to enable AI tools for medical imaging.
"AI has the potential to be groundbreaking in healthcare and medical imaging," says Prof. Roland Wiest, Deputy Director of the Institute of Diagnostic and Interventional Neuroradiology at the University Hospital of Bern and the University of Bern, Switzerland, and leader of several educational initiatives in radiology to promote wider use of AI-based technologies.
BASF Venture Capital invests in the future of plastics
The chemical giant in Ludwigshafen is still in the digital turnaround. Analysts are increasingly rating the share a "sell" because Germany's current energy policy makes it a less to cash unattractive location.
The chemical giant in Ludwigshafen is still undergoing a digital turnaround. Analysts are increasingly downgrading the stock to "sell" as Germany is considered less attractive or even unappealing due to the current energy policy in place.
Nevertheless, innovations are needed for the industry giant to make further progress in new and old markets. BASF's venture arm (BVC) announced that it would invest in the Swiss startup DePoly. DePoly is a sustainable plastics solutions provider developing a unique chemical recycling technology.
The Company, founded in 2020, has developed a chemical recycling technology that converts mixed post-consumer and post-industrial polyester plastic waste and polyester-containing fabrics and fibres into their original high-quality raw materials. The process is energy-efficient as it occurs at room temperature and normal pressure without prior sorting, pre-washing, or removal of contaminants.
With this investment, BVC underlines BASF's ongoing commitment to developing sustainable solutions for a circular economy. BVC, together with Wingman Ventures, led DePoly's EUR 12.5 million seed financing round, which included participation from Beiersdorf, Infinity Recycling, CIECH Ventures, Angel Invest and others.
The sum of the financing round will enable DePoly to accelerate the scaling and development of its depolymerization process. This will allow for the construction of a demonstration plant, which is expected to be operational in 2024.
Cardiovascular risk factors and diseases will increase dramatically in the US in the coming decades. This will require increased research and development of therapies to treat cardiovascular disease, such as that of Cardiol Therapeutics. In addition, the partnership between Bayer and the Inselspital Bern demonstrates the potential of AI in medical imaging. Radiologists are supported in their work, which can lead to improved diagnosis and treatment and improved processes in the hospital. BASF Venture Capital invests in the Swiss startup DePoly, which has developed an innovative chemical recycling technology. This underlines BASF's commitment to sustainable solutions in the circular economy.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
